Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Updated analysis of KEYNOTE-426: pembro plus axitinib vs sunitinib in mRCC

Elizabeth Plimack, MD, MS, Fox Chase Cancer Center, Philadelphia, PA, discusses the updated analysis of the KEYNOTE-426 trial (NCT02853331). This study evaluated the efficacy and safety of pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for patients with advanced renal cell carcinoma (mRCC). Pembrolizumab in combination with axitinib continued to demonstrate superior and durable antitumor activity versus sunitinib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.